ReviewBlood and lymphatic cancer : targets and therapy2016
Managing treatment-related peripheral neuropathy in patients with multiple myeloma.
Review in Blood and lymphatic cancer : targets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 44 citations in OpenAlex.
- Neurofilament light chain levels indicate acute axonal damage under bortezomib treatment.Journal of neurology · 2023Trial
- Perioperative considerations for patients with multiple myeloma.European journal of anaesthesiology and intensive care · 2026Review
- Safety considerations for cereblon-recruiting targeted protein degraders.Nature reviews. Drug discovery · 2026Review
- Identifying Sexuality and Intimacy Needs in Patients with Multiple Myeloma: A Cross-Sectional Survey.Acta haematologica · 2026Article
- Review
- Cytokine Dynamics in Bortezomib-Induced Peripheral Neuropathy: Challenges in Translating Preclinical Findings to Humans.Journal of the peripheral nervous system : JPNS · 2026Observational
- Risk Stratification Strategies and Implementation of Exercise Training in Patients with Multiple Myeloma.Current oncology reports · 2025Review
- Peripheral Neuropathy Associated With Proteasome Inhibitors and Immunomodulatory Drugs: A Pharmacovigilance Disproportionality Analysis Using VigiBase.Pharmacology research & perspectives · 2025Article
- A pilot study of disulfiram for individuals with persistent symptoms despite prior antibiotic treatment for Lyme disease.Frontiers in medicine · 2025Article
- Bortezomib-induced neuropathy in multiple myeloma manifesting as foot drop due to peroneal nerve palsy.BMJ case reports · 2024Article
- Review
- The three pillars in treating antibody-mediated encephalitis.Wiener klinische Wochenschrift · 2024Review
- Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma.Frontiers in oncology · 2024Review
- Thalidomide upper limb embryopathy - pathogenesis, past and present management and future considerations.The Journal of hand surgery, European volume · 2023Review
- Animal models of chemotherapy-induced peripheral neuropathy for hematological malignancies: A review.Ibrain · 2023Review
- Bortezomib-induced neurotoxicity in human neurons is the consequence of nicotinamide adenine dinucleotide depletion.Disease models & mechanisms · 2022Article
- Refractory postherpetic neuralgia in a multiple myeloma patient with lenalidomide maintenance therapy: a case report.The Journal of international medical research · 2022Article
- Bortezomib-Induced Epigenetic Alterations in Nerve Cells: Focus on the Mechanisms Contributing to the Peripheral Neuropathy Development.International journal of molecular sciences · 2022Article
- Practical guidance for new multiple myeloma treatment regimens: A nursing perspective.Seminars in oncology · 2022Review
- Soluble epoxide hydrolase inhibition alleviates chemotherapy induced neuropathic pain.Frontiers in pain research (Lausanne, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral neuropathy is one of the most important complications of multiple myeloma treatment. Neurological damage can be observed at the onset of the disease, due to the effect of monoclonal protein or radicular compression, but more often is treatment related. Vinca alkaloids in the past era, and more recently, thalidomide and bortezomib are mainly responsible. Degeneration of dorsal root ganglion is common, prevalently related to angiogenesis inhibition and cytokine modulation in the case of thalidomide and inhibition of the ubiquitin proteasome system in the case of bortezomib. Sensory neuropathy and neuropathic pain are more common; motor neuropathy and autonomic damage are less frequently observed. Neurotoxicity often affects patient's quality of life and requires dose modification or withdrawal of therapy, with a possible effect on the overall response. A prompt recognition of predisposing factors (such as diabetes mellitus, alcohol abuse, vitamin deficiencies, or viral infections) and appearance of signs and symptoms, through a periodic neurological assessment with appropriate scales, is extremely important. Effective management of treatment at the emergence of peripheral neuropathy can minimize the incidence and severity of this complication and preserve therapeutic efficacy. Dose adjustment could be necessary during treatment; moreover, gabapentin or pregabalin, tricyclic antidepressants, serotonin and norepinephrine reuptake inhibitors, carbamazepine, and opioid-type analgesics are suggested according to the pain severity. Some authors reported that patients who develop peripheral neuropathy during their multiple myeloma treatments presented a particular gene expression profile; therefore, future studies could be helpful for a better understanding of possible biological pathways underlying neurotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.